Location History:
- Stirling, NJ (US) (2009 - 2019)
- Sterling, NJ (US) (2023)
Company Filing History:
5 out of 90 
2 out of 2,078 
1 out of 832,880 Years Active: 2009-2025
Title: Innovations by Tatiana Vener in Acute Myeloid Leukemia Treatment
Introduction
Tatiana Vener is an accomplished inventor based in Stirling, NJ (US), known for her significant contributions to the field of medical research, particularly in the treatment of Acute Myeloid Leukemia (AML). With a total of eight patents to her name, her work focuses on improving treatment outcomes for patients, especially the elderly.
Latest Patents
One of her latest patents is a method for determining the response of Acute Myeloid Leukemia patients to treatment with farnesyltransferase inhibitors. This innovative method allows for the rapid identification of AML patients who are likely to respond positively to a combination of farnesyltransferase inhibitors and various chemotherapy agents, including etoposide and tamoxifen. The method utilizes whole blood samples instead of traditional bone marrow samples, enhancing accuracy and reducing invasiveness. It evaluates a two-gene expression ratio (RASGRP1:APTX) to predict treatment responses, offering a promising approach for elderly patients who may achieve recovery rates comparable to younger patients.
Career Highlights
Throughout her career, Tatiana has worked with notable companies such as Bioarray Solutions Ltd. and Janssen Pharmaceutica NV. Her experience in these organizations has contributed to her expertise in developing innovative medical solutions.
Collaborations
Tatiana has collaborated with esteemed colleagues, including Michael Seul and Sukanta Banerjee, to advance her research and patent developments.
Conclusion
Tatiana Vener's work exemplifies the impact of innovation in the medical field, particularly in enhancing treatment options for Acute Myeloid Leukemia patients. Her contributions continue to pave the way for improved patient care and outcomes.